Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15710980 | 1.00 | LMNA (0.39) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL4464987 | 0.80 | LMNA (0.37) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL2713252 | 0.77 | LMNA (0.39) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL10759607 | 0.77 | LMNA (0.39) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL10759619 | 0.77 | LMNA (0.39) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL15711112 | 0.76 | TDP1 (0.33) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL15711108 | 0.76 | TDP1 (0.33) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL24991859 | 0.75 | — | — | |
| SCHEMBL12975431 | 0.75 | TSHR (0.38) | LMNATDP1 | |
| SCHEMBL28850217 | 0.74 | LMNA (0.37) | LMNAALOX15BLMPMP22TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1063417-C | Method for inhibiting hydrate formation | EXXON PRODUCTION RESEARCH CO (US) | 2001-03-21 | — | — | CN | claimed |
| EP-4245565-A1 | TIRE | Sumitomo Rubber Industries, Ltd. (JP) | 2023-09-20 | — | — | EP | disclosed |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | LMNA 4213/4885ALOX15 1353/4885BLM 865/4885 |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | LMNA 4213/4885ALOX15 1353/4885BLM 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.